Foetal valproate spectrum disorder (FVSD)
Evidence-based neurology checklist on foetal valproate spectrum disorder (fvsd): Essential diagnostic criteria Exposure to Valproate in pregnancy Exclusion of other potential causes Normal microarray-CGH and Fragile X studies Facial dysmorphism Skeletal features Neurological features Systemic…
Essential diagnostic criteria
- Exposure to Valproate in pregnancy
- Exclusion of other potential causes
- Normal microarray-CGH and Fragile X studies
Facial dysmorphism
Skeletal features
Neurological features
Systemic features
Management
References
- Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, de Jong-van den Berg LT; EUROCAT Antiepileptic Study Working Group. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362:2185-2193.
- Verrotti A, Mencaroni E, Castagnino M, Zaccara G. Foetal safety of old and new antiepileptic drugs. Expert Opin Drug Saf 2015; 14:1563-1571.
- Tomson T, Battino D, Bonizzoni E, et al; EURAP Study Group. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology 2015; 85:866-872.
- Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16:695-714.
- Clayton-Smith J, Bromley R, Dean J, et al. Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet J Rare Dis 2019; 14:180.
- And 9 more. Subscribe to see the full list
